INTRODUCTION

Endometrial cancer is one of the common malignant conditions among postmenopausal women. The common presenting complaint of endometrial cancer was uterine bleeding. The bone metastasis among endometrial cancer was very rare ranging from 2% to 15% and in cases where metastasis occurred usually restricted to pelvis or vertebrae. So, here, we present a case of endometrial adenocarcinoma with a bony metastasis to the sacrum.

CASE PRESENTATION

A postmenopausal married woman was admitted to the department of gynecology at the age of 61 due to abnormal uterine bleeding. There was not any specific past medical and familial history and the patient did not take any specific medications. She mentioned that the bleeding was presented as occasional spotting. The physical examinations including the physical examination of the vagina, cervix, and uterus, were all normal. A pipelle biopsy reported the presence of adenocarcinoma, and therefore, the patient underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO), subsequently. The pathologic report showed grade 1 adenocarcinoma that cancer cells had spread halfway or more into the myometrium without any extension outside of the uterus without extension outside the body of the uterus. The tumor was located at the fundus of it (FIGO stage IB). The patient underwent observation alone.
Six months after surgery, she was referred to the department due to new-onset bone pain at her pelvic region. Physical examination showed tenderness at the middle part of sacrum and the proximal parts of femur. A whole-body Tc-99m MDP bone scan (WBBS) and computed tomography (CT) scanning of the abdomen/pelvis were requested which showed a single osteolytic metastatic lesion at the greater trochanter of the left femur (Figure 1). Because of the rarity of bone metastasis in patients with endometrial adenocarcinoma and solitary nature of lesion, a CT-guided core needle biopsy was requested. The pathologic examinations confirmed the diagnosis of bone metastasis from endometrial carcinoma.

Palliative radiotherapy with a total dose of 30 Gy delivered in 10 fractions to the metastatic lesion provided a remarkable pain relief. Subsequently, the patients received docetaxel 75 mg/m² and carboplatin area under the concentration-time curve 6 with zoledronic acid 4 mg every 3 weeks for 6 cycles. After completion of docetaxel/carboplatin chemotherapy, zoledronic acid was continued every 4 weeks. Within 12 months of follow-up, the patient was symptom-free and annual imaging showed no recurrence of disease and no progression of bony lesion. However, three months later, she complained of chronic cough which had begun one month ago. A CT scan of thorax showed a solitary pulmonary nodule at the right upper lobe. Due to appropriate time interval between the last platinum-based chemotherapy and the current disease progression, a rechallenge with docetaxel/carboplatin chemotherapy regimen plus bevacizumab (15 mg/kg every 3 weeks) was initiated and delivered for six cycles. A 12-month follow-up showed no radiologic and symptomatic progression of disease.

3 | DISCUSSION

Endometrial adenocarcinoma can be easily detected during stage 1 because of its early presentation as abnormal vaginal bleeding and most commonly occurs in postmenopausal women of age greater than 60 years. The risk factors of endometrial cancers include obesity, uncontrolled exposure to estrogen, hypertension, PCOS, diabetes, and in people taking hormone therapy for breast cancer (use of tamoxifen). Using the birth control pills (combination of estrogen and progesterone) was found to reduce the risk of endometrial cancers.2,3

In endometrial cancer, mostly metastasis occurs to lymph nodes, liver, and lungs. The common pathway of metastasis was through lymph-vascular route or by direct invasion. Till now, only 2%-6% of endometrial cancers has reported with metastasis to bone.3 Due to bone metastases, osteolytic complication may arise in patients and it was due to the tumor-induced alterations of the Osteoprotegerin (OPG)-RANKL-RANK system.4 The bone metastases cause several skeletal complications in cancer patients and affect the quality of life of the patient. Bone fractures, cancer-induced bone pain, spinal cord compression, cancer cachexia, and hypercalcemia were common skeletal complications associated with bone metastases.5

In our case, metastasis occurred to sacrum and the metastasis of the endometrial cancers to sacrum is very rare, usually limited to pelvis and vertebrae. But, in literature, there were cases where metastasis occurred to tibia, temporal bone, and skull.3,6-9 In a case by Madabhavi et al., endometrial cancer was reported in a 66-year-old postmenopausal women and metastasis was occurred to tarsal bones.7 The case by Madabhavi et al. was managed by systemic chemotherapy consisting of carboplatin and paclitaxel (175 mg/m²) in 6 cycles of 21 days intervals, whereas in our case, it was managed by docetaxel/carboplatin chemotherapy, zoledronic acid, and bevacizumab chemotherapy. Early-stage cancers can be cured using radiotherapy and chemotherapy, but last-stage cancers need surgical removal of the tissue. Carboplatin and paclitaxel are commonly used for treating metastatic endometrial carcinoma.3,7 Regarding the recurrence of the cancer, the patient should be educated regarding symptoms and preventive measures.
Ucella et al. (2013) reported 19 patients (out of 1632 patients) with bone metastases of endometrial cancer. The lesions were detected in the spine and hip mostly, and radiotherapy was the treatment of choice in all patients. Moreover, the presence of bone metastasis in other parts have been reported.

Considering the new innovation in the management of malignant disease and pivotal role of genetic assessment in the treatment of endometrial cancer (role of POLE and P53 mutations), new reports should consider these genetic changes as well.

4 | CONCLUSION

Despite the rarity of condition, any new-onset bone pain in patients with endometrial cancer should be assessed for bone metastasis.

AUTHOR CONTRIBUTIONS

M.M., T.K.S., and A.E. contributed to conception, design and drafting of the manuscript. M. Gh and M.A.F. contributed to data collection. M.A.F. and D.F. contributed to drafting of the manuscript. D.F. supervised the study. All authors approved the final version for submission.

ACKNOWLEDGMENTS

We thank the patient and her guardians for giving their consent for the publication of this case report.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data sets used and/or analyzed during the current study are available from the corresponding authors per request.

ETHICAL APPROVAL

The study was approved by Babol and Qom Universities of medical Sciences. The study conforms to recognized standards of Declaration of Helsinki. An informed written consent form was obtained from the patient.

CONSENT

Written informed consent was obtained from the patient to publish this report in accordance with the journal’s patient consent policy.

ORCID

Danial Fazilat-Panah https://orcid.org/0000-0003-4194-6575

REFERENCES

1. Abdul-Karim FW, Kida M, Wentz WB, et al. Bone metastasis from gynecologic carcinomas: a clinicopathologic study. Gynecol Oncol. 1990;39(2):108-114. doi:10.1016/0090-0235(90)90414-g

2. Endometrial Cancer. Mayo Clinic. Available at: https://www.mayoclinic.org/diseases-conditions/endometrial-cancer/symptoms-causes/syc-20352461 [Last Accessed on 26 December 2021]

3. Madabhavi IV, Patel A, Sarkar MS, Modi MG, Aagre S. Isolated acrometastasis: a rare presenting feature of endometrial carcinoma. J can Res Ther. 2019;15:1402-1404. doi:10.4103/jcrt.JCRT_394_15

4. Berenson JR, Rajdev L, Broder M. Pathophysiology of bone metastases. Cancer Biol Ther. 2006;5(9):1078-1081. doi:10.4161/cbt.5.9.3306

5. Tsuzuki S, Park SH, Eber MR, Peters CM, Shiozawa Y. Skeletal complications in cancer patients with bone metastases. Int J Urol. 2016;23(10):825-832. doi:10.1111/iju.13170

6. Kaya A, Olmezoglu A, Eren CS, et al. Solitary bone metastasis in the tibia as a presenting sign of endometrial adenocarcinoma: a case report and the review of the literature. Clin Exp Metastasis. 2007;24(2):87-92. doi:10.1007/s10585-007-9061-2

7. Wong B, Addison AB, Swords CE, Patil S. Recurrent endometrial carcinoma metastasis to the temporal bone and skull base. Ann R Coll Surg Engl. 2021;103(10):e338-e340. doi:10.1308/rcsann.2021.0055

8. Makris GM, Mene J, Battista MI, et al. Endometrial carcinoma with tibial bone metastasis: a case report and literature review. J Obstet Gynaecol. 2018;38(8):1039-1047. doi:10.1080/01443615.2017.1420759

9. Söylemez MS, Kemah B, Söylemez UPO, Klilç B, Ozkan K. Endometrial adenocarcinoma recurrence presenting with tibial metastasis: report of a case. Int J Surg Case Rep. 2017;36:15-17. doi:10.1016/j.ijscr.2017.04.009

10. Ucella S, Morris JM, Bakkum-Gamze JN, Keenev GL, Podratz KC, Mariani A. Bone metastases in endometrial cancer: report on 19 patients and review of the medical literature. Gynecol Oncol. 2013;130(3):474-482. doi: 10.1016/j.ygyno.2013.05.010

11. Mustafa MS, Al-Nuaim L, Inayat-Ur-Rahman N. Scalp and cranial bone metastasis of endometrial carcinoma: a case report and literature review. Gynecol Oncol. 2001;81(1):105-109. doi:10.1006/gync.2000.6038

12. Javadnia SA, Shahidsales S, Fanipakdel A, et al. Therapeutic potential of targeting the Wnt/β-catenin pathway in the treatment of pancreatic cancer. J Cell Biochem. 2019;120(5):6833-6840.

13. Javadinia SA, Shahidsales S, Fanipakdel A, et al. The esophageal cancer and the PI3K/AKT/mTOR signaling regulatory microRNAs: a novel marker for prognosis, and a possible target for immunotherapy. Curr Pharm Des. 2018;24(39):4646-4651.

14. Javadinia SA, Gholami A, Joudi Mashhad M, et al. Antitumoral effects of low molecular weight heparins: a focus on the treatment of esophageal cancer. J Cell Physiol. 2018;233(10):6523-6529.

15. Taghizadeh Kermani A, Hosseini S, Fanipakdel A, et al. A randomized clinical trial on the antitumoral effects of low
molecular weight heparin in the treatment of esophageal cancer. *J Cell Physiol.* 2019;234(4):4191-4199.

16. Fazilat-Panah D, Vakili Ahrari Roudi S, Keramati A, et al. Changes in cytokeratin 18 during neoadjuvant chemotherapy of breast cancer: a prospective study. *Iran J Pathol.* 2020;15(2):117-126.

17. León-Castillo A, Britton H, McConchey MK, et al. Interpretation of somatic POLE mutations in endometrial carcinoma. *J Pathol.* 2020;250(3):323-335. doi: 10.1002/path.5372

18. Casey L, Singh N. POLE, MMR, and MSI testing in endometrial cancer: proceedings of the ISGyP companion society session at the USCAP 2020 annual meeting. *Int J Gynecol Pathol.* 2021;40(1):5-16. doi:10.1097/PGP.0000000000000710

19. Nakamura M, Obata T, Daikoku T, Fujiwara H. The association and significance of p53 in gynecologic cancers: the potential of targeted therapy. *Int J Mol Sci.* 2019;20(21):5482. doi:10.3390/ijms20215482

How to cite this article: Mirzaei M, Eshraghi A, Ghoddoosi M, et al. Endometrial adenocarcinoma with bone metastasis: A case report. *Clin Case Rep.* 2022;10:e05836. doi:10.1002/ccr3.5836